FinDogFinDog
Wednesday, September 16, 2026Closing data · 4:00 PM ET
English
Log in

VRTX

Vertex PharmaceuticalsNASDAQ · Biotechnology · Health Care
Previous close
513.26
Change
−1.37 / −0.27%
FinDog View
Neutral
52-Week Range
374.17 – 560.25
P/E (TTM)
29.7
Forward P/E
24.0
Based on consensus earnings for the next 12 months
Market Cap
$121B
1M
−0.44%
S&P 500 −2.41% over same period
Volume / Avg Volume
639K / 942K
0.68× average

Price History

Closing price · USD1M6M1Y5Y
400450500550600FY26 Q2 EarningsFY26 Q1 Earnings2026-032026-052026-062026-082026-09

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 28.71M6M1Y5Y
2426283032342026-032026-052026-062026-082026-09

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis
FY2026 Q2
Quarter ended 2026-06
2026-08-03$3.3B4.73 / 4.83+1.70%Pending
FY2026 Q1
Quarter ended 2026-03
2026-05-04$3.0B4.47 / 4.40−1.28%Pending
FY2025 Q4
Quarter ended 2025-12
2026-02-12—— / —+5.69%Pending
FY2025 Q3
Quarter ended 2025-09
2025-11-03—— / —−1.02%Pending
FY2025 Q2
Quarter ended 2025-06
2025-08-04—— / —−20.60%Pending
FY2025 Q1
Quarter ended 2025-03
2025-05-05—— / —−10.03%Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 52 of its 5-year rangeMid-range
5-year range 26.5 – 32.6 · Median 29.6
Last 4 quarters: $2.0B in buybacks + $0 in dividends, 1.66% of market cap combined
P/E (TTM)
29.7
P/B
6.5
P/S
10.4
PEG
1.91
Earnings Reaction
Over the last 6 reports, the stock moved ±6.7% on average on the first trading day after, rising 2 times
Most recent +1.70%
Volatility & Correlation
1-year beta 0.42 · Correlation with S&P 500 0.21Low beta
Annualized volatility 27% vs. 14% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 5 · $2.8MNet selling $2.8M
  • 07-02McKechnie DuncanEVP, Chief Commercial OfficerSell$0.80M1,541 shares · Avg price 519.00
  • 07-02Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sell$0.79M1,500 shares · Avg price 524.99
  • 07-01Liu JoyEVP and Chief Legal OfficerSell$0.42M828 shares · Avg price 502.71
  • 06-26Bozic CarmenEVP and CMOSell$0.29M596 shares · Avg price 482.50
  • 06-18Bozic CarmenEVP and CMOSell$0.47M1,020 shares · Avg price 462.17
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q23.33+12.5%85.3%1.251.101.014.31
FY2026 Q12.99+7.8%86.8%1.141.031.294.02
FY2025 Q43.19+9.5%85.4%1.211.190.354.64
FY2025 Q33.08+11.0%86.5%1.191.081.144.20
FY2025 Q22.96+12.1%86.3%1.151.030.933.99
FY2025 Q12.77+3.0%86.9%0.630.650.782.49
FY2024 Q42.91+15.7%85.5%1.030.910.493.62
FY2024 Q32.77+11.6%85.8%1.121.051.304.01
FY2024 Q22.65+6.1%85.9%-3.51-3.59-3.82-13.92
FY2024 Q12.69+13.3%87.3%1.141.101.244.21
FY2023 Q42.52+9.3%85.4%0.990.970.183.71
FY2023 Q32.48+6.4%87.2%1.041.041.233.97

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView
VRTXVertex Pharmaceuticals$121B29.7+12.5%85.3%−0.44%Neutral
LLYLilly (Eli)$1.07T39.9+47.7%85.8%−3.83%BullishCompare
JNJJohnson & Johnson$644B30.6+6.6%68.2%+1.87%BullishCompare
ABBVAbbVie$464B73.7+10.2%74.7%+4.87%NeutralCompare
MRKMerck & Co.$358B112.2+5.1%73.5%+6.57%NeutralCompare
UNHUnitedHealth Group$337B23.9+0.4%88.1%−5.15%NeutralCompare
TMOThermo Fisher Scientific$240B34.4+10.5%—+10.75%BullishCompare
AMGNAmgen$203B23.3+9.5%72.0%−10.26%NeutralCompare
GILDGilead Sciences$183B—+10.2%79.8%+6.31%NeutralCompare